Clinical pharmacology of acetylsalicylic acid as an anti-thrombotic agent
Currently, acetylsalicylic acid (ASA) is one of the main medications in cardiovascular prevention. Preventive ASA therapy has some specific pharmacokinetic and pharmacodynamic features, also depending on the medication form. The maximal ASA effectiveness is observed for low doses of 75-150 mg/d. The...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
1970-01-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1651 |
| Summary: | Currently, acetylsalicylic acid (ASA) is one of the main medications in cardiovascular prevention. Preventive ASA therapy has some specific pharmacokinetic and pharmacodynamic features, also depending on the medication form. The maximal ASA effectiveness is observed for low doses of 75-150 mg/d. The main adverse effect (AE) of preventive ASA therapy is gastro-toxicity, which could be reduced by prescribing low ASA doses, being aware of other risk factors, and choosing optimal medication forms. Gastro-intestinal (GI) AE could also be prevented and treated with proton pump inhibitors, while antacids do not reduce ASA gastro-toxicity. Comparing to standard ASA forms, intestine-soluble forms are characterised by lower risk of gastric ulcers and erosions, heartburn, and pain symptoms. |
|---|---|
| ISSN: | 1728-8800 2619-0125 |